Immunotherapy using allogeneic squamous cell tumor-dendritic cell fusion hybrids

Walter T. Lee, Chunrui Tan, Gary Koski, Suyu Shu, Peter A Cohen

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background Tumor-associated antigens (TAAs) are known to be immunotherapy targets; thus tumor-sharing TAA may be used as a fusion hybrid partner to confer protection against subsequent tumor challenge. Methods The squamous cell carcinomas (SCCs), SCCVII and B4B8, were used in C3H/HEN mice: SCCVII (H-2 k) is syngeneic, B4B8 (H-2d) is allogeneic. Experiments using tumor alone included hyperimmunization schedule, subdermal and intranodal routes. Mice were challenged 2 weeks later. Fusion hybrids were created from both SCC tumor cell lines and syngeneic dendritic cells (DCs). These were delivered intranodally for immunization, and mice were challenged with tumor 2 weeks later. Results Only syngeneic tumor given subdermally was able to protect after tumor challenge 2 weeks later. Hyperimmunization schedule did not alter these findings. However, fusion hybrid immunization from both allogeneic and syngeneic SCCs conferred protection after tumor challenge. Conclusions Allogeneic tumor-DC fusion hybrids targeting TAA can protect against subsequent tumor challenge.

Original languageEnglish (US)
Pages (from-to)1209-1216
Number of pages8
JournalHead and Neck
Volume32
Issue number9
DOIs
StatePublished - Sep 2010

Fingerprint

Cell Fusion
Immunotherapy
Dendritic Cells
Epithelial Cells
Neoplasms
Neoplasm Antigens
Squamous Cell Carcinoma
Immunization
Appointments and Schedules
Inbred C3H Mouse
Tumor Cell Line

Keywords

  • dendritic cell
  • fusion hybrid
  • immunotherapy
  • squamous cell carcinoma
  • vaccine

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Immunotherapy using allogeneic squamous cell tumor-dendritic cell fusion hybrids. / Lee, Walter T.; Tan, Chunrui; Koski, Gary; Shu, Suyu; Cohen, Peter A.

In: Head and Neck, Vol. 32, No. 9, 09.2010, p. 1209-1216.

Research output: Contribution to journalArticle

Lee, Walter T. ; Tan, Chunrui ; Koski, Gary ; Shu, Suyu ; Cohen, Peter A. / Immunotherapy using allogeneic squamous cell tumor-dendritic cell fusion hybrids. In: Head and Neck. 2010 ; Vol. 32, No. 9. pp. 1209-1216.
@article{fe9298231c934e0d9913a872d9fe577f,
title = "Immunotherapy using allogeneic squamous cell tumor-dendritic cell fusion hybrids",
abstract = "Background Tumor-associated antigens (TAAs) are known to be immunotherapy targets; thus tumor-sharing TAA may be used as a fusion hybrid partner to confer protection against subsequent tumor challenge. Methods The squamous cell carcinomas (SCCs), SCCVII and B4B8, were used in C3H/HEN mice: SCCVII (H-2 k) is syngeneic, B4B8 (H-2d) is allogeneic. Experiments using tumor alone included hyperimmunization schedule, subdermal and intranodal routes. Mice were challenged 2 weeks later. Fusion hybrids were created from both SCC tumor cell lines and syngeneic dendritic cells (DCs). These were delivered intranodally for immunization, and mice were challenged with tumor 2 weeks later. Results Only syngeneic tumor given subdermally was able to protect after tumor challenge 2 weeks later. Hyperimmunization schedule did not alter these findings. However, fusion hybrid immunization from both allogeneic and syngeneic SCCs conferred protection after tumor challenge. Conclusions Allogeneic tumor-DC fusion hybrids targeting TAA can protect against subsequent tumor challenge.",
keywords = "dendritic cell, fusion hybrid, immunotherapy, squamous cell carcinoma, vaccine",
author = "Lee, {Walter T.} and Chunrui Tan and Gary Koski and Suyu Shu and Cohen, {Peter A}",
year = "2010",
month = "9",
doi = "10.1002/hed.21323",
language = "English (US)",
volume = "32",
pages = "1209--1216",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Immunotherapy using allogeneic squamous cell tumor-dendritic cell fusion hybrids

AU - Lee, Walter T.

AU - Tan, Chunrui

AU - Koski, Gary

AU - Shu, Suyu

AU - Cohen, Peter A

PY - 2010/9

Y1 - 2010/9

N2 - Background Tumor-associated antigens (TAAs) are known to be immunotherapy targets; thus tumor-sharing TAA may be used as a fusion hybrid partner to confer protection against subsequent tumor challenge. Methods The squamous cell carcinomas (SCCs), SCCVII and B4B8, were used in C3H/HEN mice: SCCVII (H-2 k) is syngeneic, B4B8 (H-2d) is allogeneic. Experiments using tumor alone included hyperimmunization schedule, subdermal and intranodal routes. Mice were challenged 2 weeks later. Fusion hybrids were created from both SCC tumor cell lines and syngeneic dendritic cells (DCs). These were delivered intranodally for immunization, and mice were challenged with tumor 2 weeks later. Results Only syngeneic tumor given subdermally was able to protect after tumor challenge 2 weeks later. Hyperimmunization schedule did not alter these findings. However, fusion hybrid immunization from both allogeneic and syngeneic SCCs conferred protection after tumor challenge. Conclusions Allogeneic tumor-DC fusion hybrids targeting TAA can protect against subsequent tumor challenge.

AB - Background Tumor-associated antigens (TAAs) are known to be immunotherapy targets; thus tumor-sharing TAA may be used as a fusion hybrid partner to confer protection against subsequent tumor challenge. Methods The squamous cell carcinomas (SCCs), SCCVII and B4B8, were used in C3H/HEN mice: SCCVII (H-2 k) is syngeneic, B4B8 (H-2d) is allogeneic. Experiments using tumor alone included hyperimmunization schedule, subdermal and intranodal routes. Mice were challenged 2 weeks later. Fusion hybrids were created from both SCC tumor cell lines and syngeneic dendritic cells (DCs). These were delivered intranodally for immunization, and mice were challenged with tumor 2 weeks later. Results Only syngeneic tumor given subdermally was able to protect after tumor challenge 2 weeks later. Hyperimmunization schedule did not alter these findings. However, fusion hybrid immunization from both allogeneic and syngeneic SCCs conferred protection after tumor challenge. Conclusions Allogeneic tumor-DC fusion hybrids targeting TAA can protect against subsequent tumor challenge.

KW - dendritic cell

KW - fusion hybrid

KW - immunotherapy

KW - squamous cell carcinoma

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=78349296408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349296408&partnerID=8YFLogxK

U2 - 10.1002/hed.21323

DO - 10.1002/hed.21323

M3 - Article

C2 - 20054852

AN - SCOPUS:78349296408

VL - 32

SP - 1209

EP - 1216

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 9

ER -